Paper Details

  1. Home
  2. Paper Details

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.

Author: Ariza-HerediaElla J, ChemalyRoy F, El ChaerFiras, El-HaddadDanielle, GulbisAlison M, MulanovichVictor E, ShahDimpy P, ShpallElizabeth J, VanichananJackapat

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Resistance to antiviral drugs is increasing, leading to higher morbidity and mortality in hematopoietic cell transplant (HCT) recipients with Cytomegalovirus (CMV) infections. Brincidofovir, a new antiviral drug, is being developed as a potential treatment for resistant CMV infections.
Paper Details　
Original Abstract of the Article :
The emergence of resistance to available antiviral drugs may cause higher Cytomegalovirus (CMV)-associated morbidity and mortality in hematopoietic cell transplant (HCT) recipients. Few novel antiviral drugs are being developed with potential effect against refractory or resistant CMV infections. Br...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.antiviral.2016.08.024

データ提供：米国国立医学図書館（NLM）

Brincidofovir: Fighting CMV Infections

The desert of [cytomegavirus (CMV)] infections can be a challenging place to navigate, especially for patients with compromised immune systems. This study investigates the potential of [brincidofovir], a new antiviral drug, to treat [refractory and resistant CMV infections] in [immunocompromised cancer patients]. The researchers found that [brincidofovir], a [prodrug of cidofovir], showed promising activity against CMV in vitro. This research offers hope for patients who are struggling with [refractory or resistant CMV infections], providing them with a potential new weapon in their fight against this challenging infection.

Hope in the Desert of CMV Infections

This study is a ray of hope in the vast desert of CMV infections. The researchers have found that brincidofovir could be a valuable tool in the fight against [refractory and resistant CMV infections] in immunocompromised patients. This could significantly improve the outcomes for patients who are currently facing limited treatment options. The study's findings are a testament to the ongoing efforts to develop new and effective treatments for challenging infections.

A New Oasis in the Desert

This study suggests that brincidofovir could provide a much-needed oasis in the desert of CMV infections. It offers a potential solution for patients who are struggling with [refractory and resistant CMV infections], giving them a new reason to be hopeful. This research underscores the importance of ongoing efforts to develop new antiviral therapies to combat the growing threat of drug-resistant infections.

Dr.Camel's Conclusion

This study reminds me of the desert – a place where even the most resourceful traveler can face unexpected challenges. CMV infections can be particularly difficult to treat, especially in immunocompromised patients. The researchers have discovered a potential new weapon in the fight against CMV infections. Brincidofovir offers a glimmer of hope in the desert of drug-resistant infections, and it's a testament to the ongoing efforts to develop new and effective therapies to combat these challenging diseases.

Date :
  1. Date Completed 2017-11-16
  2. Date Revised 2020-03-16
Further Info :

Pubmed ID

27582067

DOI: Digital Object Identifier

10.1016/j.antiviral.2016.08.024

Related Literature

Article Analysis
・Side Effects of ganciclovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.